Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Burstein on Pathological Complete Response

January 20th 2012

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

PARP Inhibition Explored in Triple-Negative Breast Cancer

January 16th 2012

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Chan Discusses the VEGF-Trap Agent Aflibercept

January 13th 2012

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Dr. Cohen Discusses Hedgehog Pathway Inhibition

January 13th 2012

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

DNA Analysis Finds First Gene Implicated in Prostate Cancer

January 12th 2012

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

From Warfare to Mainstay: Mustard Derivatives Play Evolving Role in Cancer Therapy

January 9th 2012

Mustard derivatives' potent lethality has ensured its descendents a place in oncology treatment regimens today, even amid advances in targeted therapies.

5 Questions on the Development of p53

December 22nd 2011

p53 coordinates a number of antiproliferative programs in response to multiple forms of stress, including low oxygen, depletion of ribonucleotides, hyperactivation of growth signaling, and many forms of DNA damage.

Targeted Cancer Therapies: Awakening the

December 22nd 2011

As its moniker As its moniker "guardian of the genome" suggests, p53 has become recognized as one of the most important cancer-related molecules in the cell.

John Theurer Cancer Center Partnership Tour

December 19th 2011

The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US.

Phosphorylation: The Master Switch of the Cell

December 15th 2011

Since its discovery, phosphorylation has come to be recognized as a global regulator of cellular activity, and abnormal phosphorylation is implicated in a host of human diseases.

5 Questions for Martin Steffen, MD, PhD

December 15th 2011

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Personalized Medicine Offers Great Hope, Great Challenges

December 14th 2011

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Channeling His Creativity Into Oncology: A "Renaissance Man" Makes a Mark in Lymphoma Research

December 8th 2011

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

Emerging Biomarker Science Presents Practical Questions

December 7th 2011

Although the use of tumor markers to evaluate patients with breast cancer is well established, the nuances involved in such testing are growing along with the emergence of novel assays and fresh research findings.

University of Pennsylvania's Abramson Cancer Center: Leaders in Groundbreaking Therapies

December 6th 2011

Established in 1973 as the University of Pennsylvania's Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education.

Dr. Mehra Discusses DNA Repair Enzymes

December 5th 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

Not All Viruses Are the Same

December 5th 2011

A look at tweaking the corruptive influence of the virus information code to selectively corrupt cancer cells while sparing (normal) cells that do not have a specific cancer phenotype.

Focusing on EGFR Resistance

December 1st 2011

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Markman Discusses Diagnostic Molecular Testing

November 30th 2011

Dr. Maurie Markman from Cancer Treatment Centers of America Discusses Diagnostic Molecular Testing